title: Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
abstract: BACKGROUND
  To investigate the immune status of health care workers (HCWs) against measles, rubella, mumps, and varicella zoster (MMRV) in Turkey and to define an appropriate vaccination program among HCWs.
  
  
  METHODS
  Voluntary HCWs from a children's hospital and a general hospital were included in the study between March and May 2005. The specific IgG antibodies against MMRV viruses were screened by ELISA.
  
  
  RESULTS
  Three hundred sixty-three HCWs participated in the study; 186 (51%) were physicians, 118 (33%) were nurses, 36 (10%) were housekeeping staff, and 23 (6%) were medical technicians. The proportion of HCWs who had antibodies against measles was 98.6%; rubella, 98.3%; mumps, 92.2%; and varicella, 98%. No association was found between the susceptibility to at least 1 of MMRV virus infections and gender, age, duration of work, profession, and department of work in analysis either among the whole study group, or each hospital. The positive predictive value for the history of varicella was 100%, whereas it was 92% for MMR. The cost of vaccination for varicella was significantly expensive without screening before vaccination. However, there was not much difference for MMR infections.
  
  
  CONCLUSIONS
  A policy based on obtaining the history of varicella infection from the staff and then screening the ones with negative history and vaccination of only seronegative HCWs was found to be appropriate.
authors.affiliation: Ankara Numune Education and Research Hospital, The First Infectious Diseases and Clinical Microbiology Clinic, Turkey.
authors.forename: Aysel
authors.initials: A
authors.lastname: Celikbas
authors.forename: Onder
authors.initials: O
authors.lastname: Ergonul
authors.forename: Sabahat
authors.initials: S
authors.lastname: Aksaray
authors.forename: Nilden
authors.initials: N
authors.lastname: Tuygun
authors.forename: Harika
authors.initials: H
authors.lastname: Esener
authors.forename: Gonul
authors.initials: G
authors.lastname: Tanir
authors.forename: Sebnem
authors.initials: S
authors.lastname: Eren
authors.forename: Nurcan
authors.initials: N
authors.lastname: Baykam
authors.forename: Engin
authors.initials: E
authors.lastname: Guvener
authors.forename: Basak
authors.initials: B
authors.lastname: Dokuzoguz
mesh_terms: D000293:Adolescent; D000328:Adult; D002644:Chickenpox / Q000453:epidemiology / Q000276:immunology*; D019433:Chickenpox Vaccine / Q000191:economics* / Q000276:immunology; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D005260:Female; D006282:Health Personnel; D006769:Hospitals, General; D006776:Hospitals, Pediatric; D006801:Humans; D017589:Immunization Programs / Q000191:economics; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008403:Mass Screening; D008457:Measles / Q000453:epidemiology / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine / Q000191:economics* / Q000276:immunology; D008875:Middle Aged; D009107:Mumps / Q000453:epidemiology / Q000276:immunology*; D012409:Rubella / Q000453:epidemiology / Q000276:immunology*; D016036:Seroepidemiologic Studies; D014421:Turkey / Q000453:epidemiology
chemical_list: D019433:Chickenpox Vaccine; D007074:Immunoglobulin G; D022542:Measles-Mumps-Rubella Vaccine